Agenus Inc. (NASDAQ:AGEN) traded up 2.7% during mid-day trading on Wednesday . The company traded as high as $5.00 and last traded at $4.97, with a volume of 655,216 shares. The stock had previously closed at $4.84.

A number of equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating on shares of Agenus in a research note on Saturday, April 30th. Maxim Group reissued a “buy” rating on shares of Agenus in a research note on Wednesday, April 27th. Finally, Zacks Investment Research raised Agenus from a “sell” rating to a “hold” rating in a research note on Tuesday, July 5th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Agenus currently has a consensus rating of “Buy” and an average price target of $10.47.

The stock’s 50-day moving average price is $4.36 and its 200 day moving average price is $3.82. The company’s market cap is $428.33 million.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Thursday, April 28th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.14. Analysts anticipate that Agenus Inc. will post ($1.36) earnings per share for the current fiscal year.

In related news, CEO Garo H. Armen purchased 100,000 shares of the company’s stock in a transaction dated Monday, May 9th. The stock was acquired at an average cost of $3.18 per share, for a total transaction of $318,000.00. Following the completion of the transaction, the chief executive officer now directly owns 1,346,026 shares of the company’s stock, valued at $4,280,362.68. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Agenus Inc (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.